己酮可可碱治疗糖尿病合并慢性肾脏病的随机试验荟萃分析
该荟萃分析纳入34项随机试验(32项提供数据),评估口服己酮可可碱对糖尿病肾脏病患者的疗效。结果显示白蛋白尿平均下降约三分之一(比值比0.69,95%CI 0.50-0.94),但异质性极大(I2=97%);≥12个月时GFR改善4.49 mL/min/1.73 m2(95%CI 0.84-8.14);终末期肾病或死亡风险比为0.90(95%CI 0.46-1.77),证据信息量严重不足。胃肠道不良事件增加三倍,严重不良事件未增加。
要点
- 己酮可可碱可降低糖尿病肾脏病患者白蛋白尿,但异质性极大且预测区间宽。
- 对GFR的改善在≥12个月时显现,但低偏倚风险试验中不显著。
- 硬终点(终末期肾病或死亡)证据极少,需专门设计的长期试验。
核心结论
- 己酮可可碱降低白蛋白尿的效应异质且依赖纳入试验,新试验中可能不复现。
- 肾脏衰竭与死亡等硬终点证据严重不足,亟需足样本长期试验。
研究设计与样本
- 系统综述与荟萃分析,检索截至2026年6月的口服己酮可可碱治疗糖尿病肾脏病的随机试验,无语言限制。
- 共纳入34项研究,32项提供数据;采用随机效应模型合并,以RoB 2评估偏倚风险,并报告预测区间与试验序贯分析。
主要发现
- 白蛋白尿平均下降约三分之一(比值比0.69,95%CI 0.50-0.94;22项研究提供23个比较),异质性极大(I2=97%),预测区间0.15-3.10。
- ≥12个月时GFR变化优于对照4.49 mL/min/1.73 m2(95%CI 0.84-8.14;5项研究提供5个比较);低偏倚风险或有一些担忧的两项试验中为2.96(-15.34至21.26)。
- 终末期肾病或死亡风险比0.90(95%CI 0.46-1.77;6项研究提供7个比较,29个事件)。
- 胃肠道不良事件风险比为3.00(95%CI 1.94-4.64),严重不良事件风险比为0.83(95%CI 0.56-1.22)。
临床怎么用
- 现有证据不支持将己酮可可碱作为糖尿病肾脏病常规治疗以预防硬终点。
- 若考虑使用以降低白蛋白尿,需权衡胃肠道不耐受风险并密切监测。
- 临床决策应优先等待报告硬终点的足样本长期试验结果。
局限性
- 白蛋白尿分析异质性极大(I2=97%),预测区间宽,效应稳定性差。
- 试验序贯分析显示白蛋白尿仅积累53%所需信息量,GFR仅11%,硬终点仅3%。
- GFR结果主要来自少数试验,低偏倚风险试验中不显著。
- 硬终点事件数少(29个事件),置信区间宽,无法排除获益或危害。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Pentoxifylline is an inexpensive anti-inflammatory agent tested in diabetic kidney disease for four decades; prior meta-analyses report reduced albuminuria. Whether it is secure, extends to kidney function, or reaches hard outcomes is unclear; we hypothesized the surrogate evidence might be conclusive and the hard-outcome evidence not. METHODS: We reviewed randomized trials of oral pentoxifylline in diabetic kidney disease to June 2026, without language restriction. Co-primary surrogate outcomes were albuminuria (ratio of means) and glomerular filtration rate (GFR) change (mean difference); the primary hard outcome was end-stage kidney disease or death (risk ratio). We pooled with random-effects models, assessed risk of bias with RoB 2, and report a prediction interval and trial sequential analysis with every estimate. RESULTS: Thirty-four studies were included, 32 contributing data. Albuminuria fell by about a third (ratio of means 0.69, 95% CI 0.50-0.94; 22 studies contributing 23 comparisons), but heterogeneity was extreme (I2 97%), the prediction interval 0.15-3.10, and only 53% of the required information had accrued, with no boundary crossed. Over ≥ 12 months, GFR changed 4.49 mL/min/1.73 m2 more favorably with pentoxifylline than with control (0.84-8.14; 5 studies contributing 5 comparisons); in two trials at low or some-concerns risk of bias it was 2.96 (-15.34 to 21.26), with 11% of the required information accrued. For end-stage kidney disease or death, 29 events in 6 studies contributing 7 comparisons gave a risk ratio of 0.90 (0.46-1.77), 3% of that required. Gastrointestinal adverse events were three times as common (3.00, 1.94-4.64); serious ones were not (0.83, 0.56-1.22). CONCLUSIONS: Pentoxifylline reduces albuminuria, but the effect is heterogeneous, depends on which trials are counted, and may not reappear in a new trial. Kidney failure and death have scarcely been tested. The priority is an adequately powered, long-term trial reporting hard endpoints; gastrointestinal intolerance should be anticipated.
引用
- Agarwal R, Leehey DJ, Navaneethan SD, et al. Pentoxifylline for chronic kidney disease in people with diabetes: a meta-analysis of randomized trials. Nephrol Dial Transplant. 2026. PMID: 42911765. doi:10.1093/ndt/gfag244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。